Celsion’s R&D Improves After Split With Hisun
This article was originally published in PharmAsia News
After Celsion and Zhejiang Hisun Pharmaceutical Co., Ltd.’s terminated their collaboration for cancer treatment ThermoDox in China due to failure to reach set clinical trial targets, the project, now belonging completely to Celsion’s, has observed three improvements.
You may also be interested in...
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.